Surgery table
| nbDMARD | Anti-TNF | ETN | INF | ADA | |
|---|---|---|---|---|---|
| Total surgeries (n) | 1012 | 4572 | 2074 | 1170 | 1328 |
| Total orthopaedic (n) | 599 | 3349 | 1535 | 859 | 955 |
| No. of patients having surgery (n) | 699 | 2816 | 1184 | 743 | 889 |
| Orthopaedic (n) | 424 | 2104 | 908 | 546 | 650 |
| Patients with more than one surgery (n) | 227 | 1051 | 486 | 266 | 299 |
| Orthopaedic (n) | 129 | 726 | 334 | 178 | 214 |
| No. postoperative VTEs (n) | 3 | 18 | 6 | 6 | 6 |
| Postop VTE crude rates (95% CI) | 3.0 (0 to 6.3) | 4.0 (2.1 to 5.8) | 2.9 (0.6 to 5.2) | 5.1 (1.0 to 9.3) | 4.5 (0.9 to 8.2) |
| Unadjusted OR (95% CI) | Referent | 1.3 (0.4 to 4.5) | – | – | – |
| Fully adjusted OR (95% CI)* | Referent | 1.9 (0.5 to 7.4) | – | – | – |
* Adjusted for age, gender, diabetes, baseline steroid exposure, smoking, hypertension, disease duration, disease severity, year of first anti-TNF drug and year of entry into study.
ADA, adalimumab; Anti-TNF, anti-tumour necrosis factor; ETN, etanercept; INF, infliximab; nbDMARD, non-biological disease-modifying antirheumatic drug; VTE, venous thrombotic event.